Early Post R/S Trading - March 14.
As expected, not able
Early Post R/S Trading - March 14.
As expected, not able to trade legacy shares today - but prices are encouraging.
Some posters obviously lying on iHub about having their sell orders in and the price "tanking" - it isn't.
Almost impossible to buy at below the equivalent of .0001 (.01) as MMs seem to have programmed in automatically outbidding any retail bids.
Too busy on other stocks at present to try anymore today.
Occasional buy opportunities between .01 and .02.
1
Bit Brother Limited (BETSF) Stock Research Links
"Per Ardua Ad Astra" - "Through Adversity To The Stars"
A very apposite motto for those who trade successfully in the OTC market..
All posts are my opinion - trade at your own risk.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Next PR Launches Innovative AI Optimization Services Next PR, an award-winning public relations firm, has recently introduced its AI Optimization Services, aimed at helping brands maintain visibility and authority in today's AI-driven digital landscape. As companies strive to adapt to the ever-changing world of artificial intelligence and search engine results generated...
Continue Reading
Overview of the Security and Vulnerability Management Market The Security and Vulnerability Management Market is on an impressive trajectory, predicted to expand from USD 17.55 billion to USD 24.07 billion by 2030, reflecting significant growth propelled by rising global vulnerabilities. Market Growth Drivers Multiple factors are contributing to this market's growth....
Continue Reading
Introducing Bybit.eu: A New Era for European Crypto Users Bybit, a leader in the cryptocurrency exchange market and the world's second-largest by trading volume, is evolving by launching Bybit.eu. This fully MiCAR-compliant platform is crafted specifically for users across the European Economic Area (EEA). Bybit EU GmbH operates this platform as a licensed Crypto-Asset...
Continue Reading
Nuvectis Pharma Reports Significant NXP900 Findings Nuvectis Pharma, Inc. (NASDAQ: NVCT), known for its pioneering work in oncology, has shared key insights regarding NXP900 at a recent prestigious cancer research meeting. This innovative drug shows considerable promise in treating advanced cancers. Based on a Phase 1a dose-escalation study, NXP900 demonstrated strong...
Continue Reading
The Unexpected Christmas Quest of Elon Musk Christmas is a time when many cherish the joy of giving and receiving gifts. However, when you are someone like Elon Musk, a dynamic CEO known for pushing boundaries with Tesla and SpaceX, a forgotten gift can turn into an extraordinary adventure. Imagine waking on Christmas Eve only to realize that you forgot to buy your...
Continue Reading
